TP53 Mutations and HBX Status Analysis in Hepatocellular Carcinomas from Iran: Evidence for Lack of Association between HBV Genotype D and TP53 R249S Mutations
- PMID: 21869931
- PMCID: PMC3159019
- DOI: 10.1155/2011/475965
TP53 Mutations and HBX Status Analysis in Hepatocellular Carcinomas from Iran: Evidence for Lack of Association between HBV Genotype D and TP53 R249S Mutations
Abstract
High incidence of HCC is mostly due to the combination of two major risk factors, chronic infection with hepatitis B (HBV) and/or C (HCV) viruses and exposure to the mycotoxin aflatoxin B(1), which induces a particular mutation at codon 249 in TP53 (R249S). Eight genotypes of HBV are diversely found in high and low incidence areas. Regardless of documented strong associations between TP53 R249S mutation and HBV genotypes B, C, A or E, there is no report of such association for genotype D despite of the presence of aflatoxin in areas with high prevalence of HBV genotype D. In Iran, 3% of the population is chronically infected with HBV, predominantly genotype D. Twenty-one histologically confirmed HCC cases from Iran were analyzed for TP53 R249S and HBV double mutations 1762(T)/1764(A), hallmarks of more pathogenic forms of HBV. We did not detect any of these mutations. In addition, we report the only case identified so far carrying both R249S mutation and chronic HBV genotype D, a patient from The Gambia in West Africa. This paper suggests that association between HBV genotype D and aflatoxin-induced TP53 mutation is uncommon, explaining the relatively lower incidence of HCC in areas where genotype D is highly prevalent.
Figures


Similar articles
-
TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia.Carcinogenesis. 2012 Jun;33(6):1219-24. doi: 10.1093/carcin/bgs068. Carcinogenesis. 2012. PMID: 22759751 Free PMC article.
-
Genome-wide association study of the TP53 R249S mutation in hepatocellular carcinoma with aflatoxin B1 exposure and infection with hepatitis B virus.J Gastrointest Oncol. 2020 Dec;11(6):1333-1349. doi: 10.21037/jgo-20-510. J Gastrointest Oncol. 2020. PMID: 33457005 Free PMC article.
-
Analysis of TP53 aflatoxin signature mutation in hepatocellular carcinomas from Guatemala: A cross-sectional study (2016-2017).Health Sci Rep. 2020 May 6;3(2):e155. doi: 10.1002/hsr2.155. eCollection 2020 Jun. Health Sci Rep. 2020. PMID: 32382660 Free PMC article.
-
The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy.Cancer Lett. 2009 Dec 1;286(1):29-37. doi: 10.1016/j.canlet.2009.02.057. Epub 2009 Apr 18. Cancer Lett. 2009. PMID: 19376640 Review.
-
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.Oncogene. 2007 Apr 2;26(15):2166-76. doi: 10.1038/sj.onc.1210279. Oncogene. 2007. PMID: 17401425 Review.
Cited by
-
TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia.Carcinogenesis. 2012 Jun;33(6):1219-24. doi: 10.1093/carcin/bgs068. Carcinogenesis. 2012. PMID: 22759751 Free PMC article.
-
Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia.PLoS One. 2017 Jul 7;12(7):e0180447. doi: 10.1371/journal.pone.0180447. eCollection 2017. PLoS One. 2017. PMID: 28686707 Free PMC article.
-
Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.BMC Infect Dis. 2015 Apr 11;15:180. doi: 10.1186/s12879-015-0916-x. BMC Infect Dis. 2015. PMID: 25886382 Free PMC article.
References
-
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. 2010;127(12):2893–2917. - PubMed
-
- Ma NF, Lau SH, Hu L, et al. COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clinical Cancer Research. 2008;14(16):5061–5068. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous